A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen-Reference-Cited by-同舟云学术

A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen

Published:2006-10 Issue:2 Volume:43 Page:153-160
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes

Author:

Johnson Margaret A,Gathe Joseph C,Podzamczer Daniel,Molina Jean-Michel,Naylor Christian T,Chiu Yi-Lin,King Martin S,Podsadecki Thomas J,Hanna George J,Brun Scott C

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference12 articles.

1. Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection

2. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients

3. Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

4. Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced Patients

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Acting Cabotegravir for HIV/AIDS Prophylaxis;Biochemistry;2021-05-24

2. Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial;Trials;2021-03-22

3. Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia;AIDS;2018-06-19

4. Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice;Pediatric Infectious Disease Journal;2017-10

5. HIV Protease Inhibitor Resistance;Handbook of Antimicrobial Resistance;2017